Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, ...

The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Sept. 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and ...

Lineage Cell Therapeutics (LCTX) announced the receipt of an induced pluripotent stem cell line containing hypoimmunity edits, from Factor ...

In a new study published in Nature Communications titled, “The reference genome of the human diploid cell line RPE-1,” researchers from University of Rome La Sapienza have produced the first reference ...

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules SEATTLE--(BUSINESS WIRE)-- As drug ...

AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of ...